Can-Fite BioPharma CANF
NYSE CANF
$1.80 -0.03 (-1.88%)
As of: Oct 23, 2026 · 3:03 PM EDT

Can-Fite BioPharma (CANF) Gains from Sales and Divestitures (2012 - 2013)

Updated

Analysis

Can-Fite BioPharma (CANF) Gains from Sales and Divestitures (2012 - 2013) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,137.66 Bn 1,106.24 Bn 19.71 Bn
2 Johnson & Johnson 636.13 Bn 556.00 Bn 17.30 Bn
3 AbbVie 505.28 Bn 478.39 Bn 12.70 Bn
4 Merck 358.10 Bn 312.48 Bn 12.21 Bn
5 Novartis Ag 292.59 Bn 256.58 Bn 11.24 Bn
6 Astrazeneca 265.81 Bn 239.50 Bn 12.86 Bn
7 Amgen 237.53 Bn 192.93 Bn 7.24 Bn
8 Gilead Sciences 194.67 Bn 168.86 Bn 6.22 Bn
9 Pfizer 171.17 Bn 117.82 Bn 10.94 Bn
10 Can-Fite BioPharma 1.48 Mn -18.23 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2013 -1,380.10
Dec 31, 2012 -2,603.87
Sep 30, 2012 -754.60
Jun 30, 2012 -16,005.49
API Access

Can-Fite BioPharma Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=CANF&period=max&api_key=YOUR_API_KEY